ClinicalTrials.gg
Not yet recruitingNCT07715565Updated Jul 20, 2026

Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial

A Phase 2 interventional study of Ipilimumab Injection and Sintilimab injection in Renal Cell Carcinoma (Kidney Cancer), Immunotherapy and Molecular Targeted Therapy, sponsored by West China Hospital. Not yet recruiting at 1 site in China. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by West China Hospital · Phase 2, Interventional, and Treatment

How we know · 7 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
14 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies testing ipilimumab in Carcinoma, Renal Cell — 5 open to participants now, 9 under way, 2 of them phase 3. Ipilimumab · Carcinoma, Renal Cell.

Planned enrollment
16th of 28
66 · median 72
Started
2026
the only one that year
Phase 2
20 of 29
4 open now
Registered
28th of 29
by date

Among the 29 studies testing ipilimumab in Carcinoma, Renal Cell, this one is the 16th largest by planned enrollment of the 28 interventional ones that give a count, is the only one that started in 2026, is one of 20 in phase 2, and was the 28th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

5 of the 29 studies testing ipilimumab in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ipilimumab

Ipilimumab: first FDA approval 2011 (YERVOY), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 14 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing ipilimumab in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

This phase II, multicenter, single-arm, open-label study evaluates first-line ipilimumab N01 plus sintilimab and lenvatinib in patients with locally advanced or metastatic TFE3-rearranged renal cell carcinoma (TFE3-rRCC), a rare subtype lacking established first-line systemic therapy. Eligible patients (age ≥14 years, ECOG ≤2, measurable disease per RECIST v1.1, no prior systemic therapy) will receive ipilimumab N01 1 mg/kg Q6W for 4 cycles, sintilimab 200 mg Q3W for up to 35 cycles, and lenvatinib 12 mg or 8 mg QD continuously. The primary endpoint is objective response rate (ORR) per RECIST v1.1. Secondary endpoints include disease control rate, duration of response, progression-free survival, overall survival, safety per NCI CTCAE v5.0, and quality of life. Exploratory biomarker analyses will assess potential predictors of treatment response.

Read the detailed description

This prospective, multicenter, single-arm, open-label, phase II clinical trial evaluates the efficacy and safety of first-line ipilimumab N01 plus sintilimab and lenvatinib in patients with locally advanced or metastatic TFE3-rearranged renal cell carcinoma (TFE3-rRCC). TFE3-rRCC is a rare, aggressive renal cell carcinoma subtype with no established standard first-line systemic therapy. Preliminary retrospective data suggest that immune checkpoint inhibitor-based combination therapy may improve clinical outcomes in this population.

Eligible patients (age ≥14 years; ECOG performance status ≤2) must have histologically confirmed, locally advanced or metastatic TFE3-rRCC diagnosed by fluorescence in situ hybridization (FISH) and/or next-generation sequencing, with measurable disease per RECIST v1.1, and no prior systemic therapy (or prior targeted therapy ≤1 month with adequate washout). A total of 66 participants will be enrolled using a Simon two-stage optimal design (21 patients in stage 1; 39 in stage 2).

Participants will receive ipilimumab N01 1 mg/kg intravenously every 6 weeks for the first 4 cycles (induction); sintilimab 200 mg intravenously every 3 weeks for up to 35 cycles (approximately 2 years); and lenvatinib 12 mg (body weight ≥60 kg) or 8 mg (body weight \<60 kg) orally once daily continuously until disease progression, unacceptable toxicity, or loss of clinical benefit.

The primary endpoint is objective response rate (ORR) assessed by investigators according to RECIST v1.1. Secondary endpoints include disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), cancer-specific survival (CSS), ORR and DCR per imRECIST, safety profile according to NCI CTCAE v5.0, and quality of life measured by EORTC QLQ-C30, FKSI-DRS, EuroQOL, and VAS. Exploratory analyses will evaluate biomarkers (tumor tissue PD-1, PD-L1, CD4, CD8, tumor-infiltrating lymphocytes, tumor mutational burden; peripheral blood cytokines, circulating tumor DNA, immune cell subsets by single-cell sequencing) and functional MRI sequences as potential predictors of treatment response.

03

Conditions studied

  • Renal Cell Carcinoma (Kidney Cancer)
  • Immunotherapy
  • Molecular Targeted Therapy

Keywords

  • Sintilimab
  • ipilimumab
  • lenvatinib
04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥14 years, any gender.
  2. confirmed locally advanced or TFE3-rearranged renal cell carcinoma (TFE3-rRCC) by FISH and/or next-generation sequencing.
  3. Stage IV disease per the 2017 8th edition TNM staging system.
  4. No prior systemic therapy with (PD-1/PD-L1 inhibitors) or targeted agents (TKI, mTORi); prior targeted therapy ≤1 month is allowed after an adequate (5.5 half-lives).
  5. (ECOG) performance status ≤2.
  6. ≥3 months.
  7. Signed and ability to comply with study visits and procedures.
  8. Willingness to provide tumor tissue and blood specimens for correlative studies.
  9. Adequate organ and bone marrow function within 14 days prior to enrollment:

Hematology: ≥1.5×10⁹/L, ≥100×10⁹/L, ≥90 g/L. Hepatic: ≤1.5×, /AST ≤2.5×ULN, albumin ≥20 g/L. Renal: serum creatinine ≤1.5×ULN or ≥50 mL/min.

Exclusion criteria

Exclusion Criteria:

  1. Active central nervous system .
  2. History of other within 3 years (different primary site or histology), except well-controlled basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ.
  3. Major surgery or severe trauma within 4 weeks prior to enrollment.
  4. Systemic (>10 mg/day prednisone equivalent) or other agents within 14 days before first dose (topical, ophthalmic, intra-articular, intranasal, inhaled, or physiologic replacement steroids are permitted).
  5. Known or suspected active disease (e.g., interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, thyroiditis), except type 1 diabetes, hypothyroidism requiring hormone replacement only, or skin conditions not requiring systemic treatment. Known allogeneic organ transplant (except corneal) or hematopoietic stem cell transplant.
  6. Known to ipilimumab N01, sintilimab, or lenvatinib.
  7. Uncontrolled severe comorbidities including:

    Active or poorly controlled severe infection. infection. Active (HBsAg-positive and HBV DNA >1×10³ IU/mL) or active (HCV antibody-positive and HCV RNA >15 IU/mL).

    Active pulmonary tuberculosis. Class III-IV congestive heart failure, symptomatic arrhythmia, uncontrolled atrial fibrillation, or below the lower limit of normal.

    Uncontrolled arterial hypertension (systolic ≥160 mmHg or diastolic ≥100 mmHg). Arterial thrombosis, embolism, or ischemia within 6 months (e.g., myocardial infarction, unstable angina, cerebrovascular accident, ).

    Uncontrolled adrenal insufficiency. Severe, non-healing wounds or ulcers; gastrointestinal disorders impairing absorption; active uncontrolled bleeding or high bleeding risk (e.g., esophageal/gastric varices requiring intervention); or unstable anticoagulation with bleeding.

  8. Any other acute or chronic medical or psychiatric condition, or laboratory abnormality, that in the opinion of the investigator increases the risk associated with study participation, may interfere with interpretation of study results, or makes the patient unsuitable for the study.
  9. Pregnant or lactating women.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Combination treatment group

    Participants receive ipilimumab 1 mg/kg intravenously every 6 weeks for the first 4 cycles (induction phase) in combination with sintilimab 200 mg intravenously every 3 weeks for up to 35 cycles (approximately 2 years), plus lenvatinib 12 mg (body weight ≥60 kg) or 8 mg (body weight \<60 kg) orally once daily continuously until disease progression, unacceptable toxicity, or loss of clinical benefit.

    Drug: Ipilimumab Injection · Drug: Sintilimab injection · Drug: Lenvatinib

Interventions

  • DrugIpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A human monoclonal antibody targeting CTLA-4.

    Also known as: Ipilimumab

  • DrugSintilimabStudies of SintilimabSintilimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Recombinant human-derived immunoglobulin G (IgG4)-type anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, by binding to PD-1 and blocking PD-1 binding to PD-L1 and PD-L2, disarms the immunosuppressive effect, activates T-cell function, and enhances T-cell immunosurveillance and killing ability against tumors to generate tumor immune response.

    Also known as: Sintilimab

  • A multi-target tyrosine kinase inhibitor (VEGFR1-3, FGFR1-4, PDGFRα, KIT, RET).

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Objective response rate is the proportion of participates with complete response (CR) or partial response (PR), based on RECIST1.1.

    Time frame: 3 years

Secondary outcomes

  1. Adverse Events (AEs)

    Adverse events are the incidence of treatment-emergent adverse events as assessed by CTCAE v5.0, including type and severity.

    Time frame: 3 years

  2. Overall Survival (OS)

    Overall survival is the time from starting treatment to still being alive.

    Time frame: 3 years

  3. Progression-Free Survival (PFS)

    Progression-free survival is assessed by investigators based on RECIST1.1, including disease progression or death from any cause.

    Time frame: 3 years

  4. Disease Control Rate (DCR)

    Disease control rate is the proportion of participates with complete response (CR), partial response (PR) or stable disease (SD), based on RECIST1.1.

    Time frame: 3 years

  5. Duration of Response (DoR)

    Duration of response is the time from first response (complete or partial response) to disease progression or death.

    Time frame: 3 years

  6. Cancer-Specific Survival (CSS)

    The period from the time the patient was diagnosed with the tumor or began treatment until death directly caused by the tumor

    Time frame: 3 years

  7. Quality of Life, European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30(EORTC QLQ-C30)

    Used to assess the multi-dimensional impact of cancer treatment on the quality of life of patients

    Time frame: 3 years

  8. Functional Assessment of Cancer Therapy Kidney Syndrome Index-Disease-Related Symptoms (FKSI-DRS)

    Used to assess the impact of specific symptoms related to kidney cancer on quality of life

    Time frame: 3 years

  9. European Quality of Life (EuroQOL)

    Used to assess the current overall health status of the patient

    Time frame: 3 years

  10. Visual Analogue Scale(VAS)

    Used to assess the pain condition and severity of the patients

    Time frame: 3 years

07

Study locations

1 site
  • West China Hospital, Chengdu, Sichuan 610000
    Chengdu, China
08

References and documents

Individual participant data

Plan to share: Yes — There is a plan to make IPD and related data dictionaries available.

Supporting information: Study protocol, Informed consent form, Clinical study report

Time frame: Data would be available starting from the time when summary data are published or otherwise made available, for 3 years.

Access criteria: Other researchers access the data by sending an email to our PI.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2029, 40 months later.

Of 185 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's planned 40 months is below that.

Counting every sponsor, half of 232 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 20, 2026
StartEst.
Aug 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07715565
Responsible party
Hao Zeng (Professor, West China Hospital) — Principal investigator
First posted
Jul 20, 2026
Start date
Aug 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Jul 20, 2026

Study contacts

Hao Zeng, Doctor
Contact
kucaizeng@163.com
+86-18980602129
Hao Zeng, Doctor
principal investigator · West China Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ipilimumab · Sintilimab · Lenvatinib

Start the discussion